Literature DB >> 11175857

Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector.

D S Steinwaerder1, C A Carlson, D L Otto, Z Y Li, S Ni, A Lieber.   

Abstract

Clinical applications of tumor gene therapy require tumor-specific delivery or expression of therapeutic genes in order to maximize the oncolytic index and minimize side effects. This study demonstrates activation of transgene expression exclusively in hepatic metastases after systemic application of a modified first-generation (E1A/E1B-deleted) adenovirus vector (AdE1-) in mouse tumor models. The discrimination between tumors and normal liver tissue is based on selective DNA replication of AdE1- vectors in tumor cells. This new AdE1- based vector system uses homologous recombination between inverted repeats to mediate precise rearrangements within the viral genome. As a result of these rearrangements, a promoter is brought into conjunction with a reporter gene creating a functional expression cassette. Genomic rearrangements are dependent upon viral DNA replication, which in turn occurs specifically in tumor cells. In a mouse tumor model with liver metastases derived from human tumor cells, a single systemic administration of replication activated AdE1- vectors achieved transgene expression in every metastasis, whereas no extra-tumoral transgene induction was observed. Here we provide a new concept for tumor-specific gene expression that is also applicable for other conditionally replicating adenovirus vectors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11175857     DOI: 10.1038/84696

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  12 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

3.  Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Authors:  H Tada; D J Maron; E A Choi; J Barsoum; H Lei; Q Xie; W Liu; L Ellis; A D Moscioni; J Tazelaar; S Fawell; X Qin; K J Propert; A Davis; D L Fraker; J M Wilson; F R Spitz
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

4.  Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines.

Authors:  Kun Zhang; Peng-Fen Gao; Pei-Wu Yu; Yun Rao; Li-Xin Zhou
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

5.  Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.

Authors:  Nelson C Di Paolo; Sebastian Tuve; Shaoheng Ni; Karl Erik Hellström; Ingegerd Hellström; André Lieber
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Cancer gene therapy using a survivin mutant adenovirus.

Authors:  M Mesri; N R Wall; J Li; R W Kim; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells.

Authors:  Dmitry M Shayakhmetov; Cheryl A Carlson; Hartmut Stecher; Qiliang Li; George Stamatoyannopoulos; André Lieber
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  In situ adenovirus vaccination engages T effector cells against cancer.

Authors:  Sebastian Tuve; Ying Liu; Khajornsak Tragoolpua; Jeffrey Daniel Jacobs; Roma Christine Yumul; Zong-Yi Li; Robert Strauss; Karl-Erik Hellström; Mary Lenora Disis; Steve Roffler; André Lieber
Journal:  Vaccine       Date:  2009-04-16       Impact factor: 3.641

9.  A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication.

Authors:  Kathrin Bernt; Min Liang; Xun Ye; Shaoheng Ni; Zong-Yi Li; Sheng Long Ye; Fang Hu; André Lieber
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.

Authors:  J A Jiménez; X Li; Y-P Zhang; K H Bae; Y Mohammadi; P Pandya; C Kao; T A Gardner
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.